Effect of quetiapine and norquetiapine on anxiety and depression in major psychoses using a pharmacokinetic approach: A prospective observational study

Clinical Drug Investigation

Volumn 32, Issue 3, 2012, Pages 213-219

  Altamura, A Carlo ^a   Moliterno, Donatella ^a   Paletta, Silvia ^a   Buoli, Massimiliano ^a   Dell'Osso, Bernardo ^a   Mauri, Massimo C ^a   Bareggi, Silvio R ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

anxiety; depression; quetiapine

Indexed keywords

BENZODIAZEPINE DERIVATIVE; LITHIUM; NORQUETIAPINE; QUETIAPINE; UNCLASSIFIED DRUG; VALPROIC ACID;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DEPRESSION; BORDERLINE STATE; CLINICAL ARTICLE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; OBSERVATIONAL STUDY; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; RATING SCALE; SCHIZOPHRENIA; STATISTICAL MODEL; SYMPTOM;

ADULT; ANTIPSYCHOTIC AGENTS; ANXIETY; DEPRESSION; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS;

EID: 84856882574     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11597330-000000000-00000     Document Type: Article

References (32)

1. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353 (12): 1209-23 (Pubitemid 41345943)
2. McIntyre RS, Soczynska JK, O Woldeyohannes H, et al. A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother 2007; 8 (9): 1211-9 (Pubitemid 47034411)
3. Kahn RS, Fleischhacker WW, Boter H, et al., EUFEST study group. Effectiveness of antipsychotic drugs in firstepisode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008 Mar 29; 371 (9618): 1085-97 (Pubitemid 351418005)
4. Tandon R, Belmaker RH, Gattaz WF, et al., for the Section of Pharmacopsychiatry, World Psychiatric Association. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008; 100: 20-38
5. Perlis RH. Treatment of bipolar disorder: the evolving role of atypical antipsychotics. Am J Manag Care 2007; 13: S178-88 (Pubitemid 350231679)
6. Kennedy SH, Lam RW, Cohen NI, et al. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001; 46 Suppl. 1: 38-58
7. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005; 66 (7): 870-86 (Pubitemid 41032829)
8. Yatham LN, Goldstein JM, Vieta E. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry 2005; 66 Suppl. 5: 40-8 (Pubitemid 40934073)
9. Baune BT, Caliskan S, Todder D. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum Psychopharmacol 2007; 22: 1-9 (Pubitemid 46178772)
10. Cruz N, Sanchez-Moreno J, Goikolea JM, et al. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol 2010; 13 (1): 5-14
11. Calabrese JR, Keck Jr PE, Macfadden W, et al. A randomized, double blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351-60 (Pubitemid 40905587)
12. Thase ME, Macfadden W, Weisler RH, et al., BOLDER II Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double blind, placebocontrolled study (the BOLDER II study). J Clin Psychopharmacol 2006; 26: 600-9 (Pubitemid 44772737)
13. Keating GM, Robinson DM. Spotlight on quetiapine in bipolar depression. CNS Drugs 2007; 21 (8): 695-7 (Pubitemid 47121796)
14. Altamura AC, Salvadori D, Madaro D, et al. Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from 12-month open-label study. J Affect Disord 2003; 76: 267-71 (Pubitemid 37013380)
15. Altamura AC, Mundo E, Dell'Osso B, et al. Quetiapine and classical mood stabilizers in the long-term treatment of bipolar disorder: a 4-year follow up naturalistic study. J Affect Disord 2008; 110: 135-41
16. Cutler AJ, Montgomery SA, Feifel D, et al. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo-and duloxetine-controlled study. J Clin Psychiatry 2009; 70 (4): 526-39
17. Pae CU, Sohi MS, Seo HJ, et al. Quetiapine XR: current status for treatment of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34 (7): 1165-73
18. Weisler R, Joyce M, McGill L, et al., Moonstone Study Group. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a doubleblind, randomized, placebo-controlled study. CNS Spectr 2009; 14 (6): 299-313
19. Bauer M, El-Khalili N, Datto C, et al. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord 2010; 127: 19-30
20. Vieta E, Grunze H. Bipolar disorder: a focus on depression. N Engl J Med 2011; 364 (16): 1581; author reply 1582
21. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: amulticentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2010; 23: 1-16
22. Pae CU, Nassir Ghaemi S, Kim TS, et al. Rapid titration versus conventional titration of quetiapine in the treatment of bipolar mania: a preliminary trial. Int Clin Psychopharmacol 2005; 20 (6): 327-30
23. Pajonk FG, Schwertner AK, Seelig MA. Rapid dose titration of quetiapine for the treatment of acute schizophrenia and acute mania: a case series. J Psychopharmacol 2006; 20 (1): 119-24
24. Hatim A, Habil H, Jesjeet SG, et al. Safety and efficacy of rapid dose administration of quetiapine in bipolar mania. Hum Psychopharmacol 2006; 21 (5): 313-8 (Pubitemid 44203214)
25. Suppes T, Datto C, Minkwitz M, et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 2010; 121: 106-15
26. Jensen NH, Rodriguiz RM, Caron MG, et al. Ndesalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008; 33 (10): 2303-12
27. Bakken GV, Rudberg I, Molden E, et al. Pharmacokinetic variability of quetiapine and the active metabolite Ndesalkylquetiapine in psychiatric patients. Ther Drug Monit 2011; 33 (2): 222-6
28. Di Benedetto B, Kühn R, Northdurfter C, et al. Ndesalkylquetiapine activates ERK1/2 to induce GDNF release in C6 glioma cells: a putative cellular mechanism for quetiapine as antidepressant. Neuropharmacology 2012; 62 (1): 209-16
29. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799-812
30. Mauri MC, Volonteri LS, Fiorentini A, et al. Two week's quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels. Expert Opin Pharmacother 2007; 8 (14): 2207-13 (Pubitemid 350001584)
31. Volonteri LS, Colasanti A, Cerveri G, et al. Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels. J Psychopharmacol 2010; 24 (8): 1193-9
32. Konstantinidis A, Hrubos W, Nirnberger G, et al. Quetiapine in combination with citalopram in patients with unipolar psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31 (1): 242-7 (Pubitemid 44959252)